VCG
ACAD icon

Vantage Consulting Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Vantage Consulting Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16
Closed -$1K – 112
2020
Q4 		$1K Buy
+16
New +$794 ﹤0.01% 1700

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Vantage Consulting Group's ACAD Position: Q1 2021 in Review

Vantage Consulting Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 16 shares — an estimated $1K sold.

Vantage Consulting Group first reported a position in ACAD in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

  • Vantage Consulting Group reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 16 Acadia Pharmaceuticals shares in Q1 2021, an estimated $1K.
  • Vantage Consulting Group first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Acadia Pharmaceuticals position peaked at $1K in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.